Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome

Life Sci. 2000 Apr 21;66(22):2213-9. doi: 10.1016/s0024-3205(00)00547-6.


The role of the cannabinoid system in morphine withdrawal was examined through long-term CB1 receptor antagonist administration in morphine pellet implanted rats. SR141716A chronic treatment (5mg/kg i.p. twice a day for four days) did not influence the development of tolerance to the morphine analgesic effect but significantly reduced the intensity of naloxone-induced opiate withdrawal in tolerant rats: Specifically there was a significant reduction in the number of digging, teeth chattering and penile licking and the incidence of diarrhoea while other signs such as writhing, head dog shakes and rearing were unaffected. These results suggest that the pharmacological treatment with SR141716A could be of some interest in ameliorating opiate withdrawal syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Animals
  • Cannabinoids / metabolism
  • Dogs
  • Drug Interactions
  • Drug Tolerance
  • Male
  • Morphine / adverse effects*
  • Morphine Dependence*
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Cannabinoid
  • Receptors, Drug / antagonists & inhibitors*
  • Receptors, Drug / metabolism
  • Rimonabant
  • Substance Withdrawal Syndrome / metabolism
  • Substance Withdrawal Syndrome / prevention & control*


  • Cannabinoids
  • Piperidines
  • Pyrazoles
  • Receptors, Cannabinoid
  • Receptors, Drug
  • Morphine
  • Rimonabant